{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:12:20Z","timestamp":1790694740010,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007929.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000}}],"reference-count":306,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007929.pub4","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T08:22:01Z","timestamp":1644999721000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer"],"prefix":"10.1002","volume":"2022","author":[{"given":"Abigail","family":"Tattersall","sequence":"additional","affiliation":[{"name":"Kingston Hospital NHS Foundation Trust; Kingston upon Thames UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Ryan","sequence":"additional","affiliation":[{"name":"The Academic Women\u2019s Health Unit, Translational Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"},{"name":"Department of Obstetrics and Gynaecology; St Michael\u2019s Hospital, Bristol, UK; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J","family":"Wiggans","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology; Cheltenham General Hospital, Glocestershire Hospitals NHS Foundation Trust; Cheltenham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Rogozi\u0144ska","sequence":"additional","affiliation":[{"name":"The Evidence-Based Medicine Consultancy Ltd; Bath UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Morrison","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology, GRACE Centre; Musgrove Park Hospital, Somerset NHS Foundation Trust; Taunton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"10.1002\/14651858.CD007929.pub4-BIB0001|cit1","unstructured":"A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3) ClinicalTrials.gov website https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01968213?term=NCT01968213&rank=1"},{"issue":"15","key":"10.1002\/14651858.CD007929.pub4-BIB0002|cit2","first-page":"625","article-title":"ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)","volume":"24","author":"Coleman","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Coleman RL Oza AM Lorusso D Aghajanian C Oaknin A Dean A ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC) Clinical Cancer Research 2018 PR06","DOI":"10.1158\/1557-3265.OVCA17-PR06"},{"issue":"10106","key":"10.1002\/14651858.CD007929.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"10106","key":"10.1002\/14651858.CD007929.pub4-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet (london, England)"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Oza AM Lorusso D Aghajanian C Oaknin A Dean A ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC) Clinical Cancer Research 2018 625 10.1158\/1557-3265.OVCA17-PR06","DOI":"10.1093\/annonc\/mdx440.034"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Colombo N Oza A Lorusso D Aghajanianet C Oaknin A alDean A Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age International Journal of Gynecologic Cancer 2019 A28 A29","DOI":"10.1136\/ijgc-2019-ESGO.29"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD007929.pub4-BIB0008|cit8","first-page":"Abstract 821P","article-title":"Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study","volume":"Conference: ESM","author":"Dean","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0009|cit9","unstructured":"Khan A O'Malley DM Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma Journal of Oncology Pharmacy Practice 2018 9 10 10.1177\/1078155217751308"},{"issue":"2 Supplement 1","key":"10.1002\/14651858.CD007929.pub4-BIB0010|cit10","first-page":"9","article-title":"Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma","volume":"Conference: 14t","author":"Khan","year":"2018","journal-title":"Journal of Oncology Pharmacy Practice"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD007929.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ygyno.2017.03.028","article-title":"Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2","volume":"Conference: 48t","author":"Konecny","year":"2017","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Konecny GE Oza AM Tinker AV Coleman RL O'Malley DM Maloney L Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2 Gynecologic Oncology 2017 2 10.1016\/j.ygyno.2017.03.028","DOI":"10.1016\/j.ygyno.2017.03.028"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0013|cit13","unstructured":"Leary A Ledermann JA Oaknin A Oza AM Lorusso D Colombo N Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes International Journal of Gynecological Cancer 2018 200 201 10.1097\/01.IGC.0000547510.84464.ba"},{"issue":"5","key":"10.1002\/14651858.CD007929.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1470-2045(20)30061-9","article-title":"Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Ledermann J","year":"2020","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"O'Malley DM Coleman RL Oza AM Lorusso D Aghajanian C Oaknin A Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma MolecularCancerTtherapeutics.\u00a0 2018 10.1158\/1535-7163.TARG-17-LB-A12","DOI":"10.1158\/1535-7163.TARG-17-LB-A12"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Swisher EM McNeish IA Coleman RL Brenton J Kaufmann SH Allen AR ARIEL 2\/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response. Journal of Clinical Oncology (Meeting Abstracts) TPS5619","DOI":"10.1200\/jco.2014.32.15_suppl.tps5619"},{"issue":"10","key":"10.1002\/14651858.CD007929.pub4-BIB0017|cit17","first-page":"1409-19","article-title":"Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2\/ENGOT-ov24): a randomised, phase 2,superiority trial","volume":"20","author":"Mirza","year":"2019","journal-title":"Lancet Oncololgy"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0018|cit18","first-page":"A129","article-title":"Quality-of-life analysis in the randomized phase ii CLIO trial comparing olaparib with standard chemotherapy in platinum-resistant recurrent ovarian cancer","volume":"29","author":"Callewaert","year":"2019","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0019|cit19","unstructured":"Circulating tumor DNA guiding (Olaparib) Lynparza\u00ae treatment in ovarian cancer Clinical Trials. gov Register 2016"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD007929.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"S617","DOI":"10.1016\/j.annonc.2020.08.956","article-title":"Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: results from the randomized phase II CLIO trial","volume":"31","author":"Vanderstichele","year":"2020","journal-title":"Annals of Oncology"},{"issue":"15_supp","key":"10.1002\/14651858.CD007929.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1200\/JCO.2019.37.15_suppl.5507","article-title":"Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer","volume":"37","author":"Vanderstichele","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD007929.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0023|cit23","unstructured":"Kaye SB ICEBERG3 http:\/\/clinicaltrials.gov\/show\/NCT00628251"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1158\/1078-0432.CCR-14-2565","article-title":"Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer","volume":"14","author":"Kummar","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007929.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1200\/jco.2012.30.15_suppl.5020","article-title":"Randomized trial of oral cyclophosphamide \u00a9 with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting","volume":"30","author":"Kummar","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD007929.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/1078-0432.CCR-14-2565","article-title":"Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer","volume":"21","author":"Kummar","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.1200\/JCO.2020.38.15_suppl.6003","article-title":"A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer","volume":"15_suppl","author":"Liu J","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0028|cit28","unstructured":"Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer Clinicl Trial. gov register 2015"},{"issue":"32","key":"10.1002\/14651858.CD007929.pub4-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"10.1002\/14651858.CD007929.pub4-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"5560","DOI":"10.1200\/JCO.2017.35.15_suppl.5560","article-title":"The successful phase 3 niraparib ENGOT-OV16\/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC)","volume":"35","author":"Del Campo","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007929.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2018.12.009","article-title":"Efficacy and safety of niraparib as maintenance treatment in older patients (\u2265\u202f70\u202fyears) with recurrent ovarian cancer: results from the ENGOT-OV16\/NOVA trial","volume":"152","author":"Fabbro","year":"2019","journal-title":"Gynecologic Oncology"},{"issue":"Supplement 5 [4","key":"10.1002\/14651858.CD007929.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"V332","DOI":"10.1093\/annonc\/mdx372.004","article-title":"Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC)","volume":"28","author":"Fabbro","year":"2017","journal-title":"Annals of Oncology"},{"issue":"Supplement 1 [4","key":"10.1002\/14651858.CD007929.pub4-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ygyno.2018.04.031","article-title":"Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16\/NOVA phase III trial","volume":"149","author":"Lord","year":"2018","journal-title":"Gynecologic Oncology"},{"issue":"[16th Biennial","key":"10.1002\/14651858.CD007929.pub4-BIB0034|cit34","first-page":"19","article-title":"Engot-ov16\/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer","volume":"26","author":"Matulonis","year":"2016","journal-title":"International Journal of Gynecological Cancer"},{"issue":"15_suppl \u00a0[ASCO","key":"10.1002\/14651858.CD007929.pub4-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.tps5625","article-title":"A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16\/NOVA trial)","volume":"32","author":"Matulonis","year":"2014","journal-title":"J Clinical Oncology"},{"issue":"15_suppl","key":"10.1002\/14651858.CD007929.pub4-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.1200\/JCO.2017.35.15_suppl.5534","article-title":"Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC)","volume":"35","author":"Matulonis","year":"2017","journal-title":"J Clinical Oncology"},{"issue":"15_suppl (Annua","key":"10.1002\/14651858.CD007929.pub4-BIB0037|cit37","article-title":"Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC)","volume":"35","author":"Matulonis","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"34","key":"10.1002\/14651858.CD007929.pub4-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1200\/JCO.19.00917.","article-title":"Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16\/NOVA Trial","volume":"37","author":"Matulonis","year":"2019","journal-title":"Journal of Clinicsl Oncology"},{"issue":"Supplement 1 [5","key":"10.1002\/14651858.CD007929.pub4-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ygyno.2019.04.016","article-title":"Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16\/NOVA trial","volume":"154","author":"Matulonis","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1002\/14651858.CD007929.pub4-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ygyno.2020.09.006","article-title":"Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16\/NOVA trial","volume":"159","author":"\u00a0Bover Barcel\u00f3","year":"2020","journal-title":"Gynecolic Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0041|cit41","first-page":"33","article-title":"Engot-ov16\/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer","volume":"[15th Biennial","author":"Mirza","year":"2014","journal-title":"International Journal of Gynecolical Cancer"},{"issue":"Supplement 2 [1","key":"10.1002\/14651858.CD007929.pub4-BIB0042|cit42","first-page":"21","article-title":"Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16\/NOVA trial","volume":"28","author":"Mirza","year":"2018","journal-title":"International Journal of Gynecological Cancer"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD007929.pub4-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"A15","DOI":"10.1136\/ijgc-2019-ESGO.18","article-title":"Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16\/NOVA trial","volume":"29","author":"Mirza","year":"2019","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0044|cit44","unstructured":"Mirza MR Matulonis U A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01847274 2013"},{"issue":"15_suppl [Annua","key":"10.1002\/14651858.CD007929.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1200\/JCO.2017.35.15_suppl.5517","article-title":"Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy","volume":"35","author":"Mirza","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD007929.pub4-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw435.26","article-title":"PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16\/NOVA trial)","volume":"27","author":"Mirza","year":"2016","journal-title":"Annals of. Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007929.pub4-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/annonc\/mdw435","article-title":"PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16\/NOVA trial)","volume":"27","author":"Mirza","year":"2016","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0049|cit49","unstructured":"A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer Clinical Trials Gov register 2018"},{"issue":"Supplement 5 [4","key":"10.1002\/14651858.CD007929.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"v330","DOI":"10.1093\/annonc\/mdx372","article-title":"Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16\/NOVA Trial","volume":"28","author":"Oza","year":"2017","journal-title":"Ann Oncol."},{"issue":"2","key":"10.1002\/14651858.CD007929.pub4-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S1470-2045(15)70044-6","article-title":"Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial","volume":"16","year":"2015","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Oza A Cibula D Benzaquen OA Poole C Mathijssen RH Sonke GS Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial Lancet Oncology 2015 16 1 87 97 \u00a0(Epub 2014 Dec 4) 10.1016\/S1470-2045(14)71135-0","DOI":"10.1016\/S1470-2045(14)71135-0"},{"issue":"1","key":"10.1002\/14651858.CD007929.pub4-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"\u00a0E6","DOI":"10.1016\/S1470-2045(14)71216-1","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncolgy"},{"issue":"Supplement 8","key":"10.1002\/14651858.CD007929.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"viii340","DOI":"10.1093\/annonc\/mdy285.158","article-title":"Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy","volume":"29","author":"Oza","year":"2018","journal-title":"Annals of Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007929.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/jco.2012.30.15_suppl.5001","article-title":"Olaparib plus paclitaxel plus carboplatin (P\/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study","volume":"30","author":"Oza","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0056|cit56","first-page":"S712","article-title":"Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1\/2 mutation (BRCAm) and interim overall survival analyses","volume":"49 Suppl 2","author":"Oza","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD007929.pub4-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"S614","DOI":"10.1016\/j.annonc.2020.08.951","article-title":"Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and\/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial","volume":"31","author":"Colombo","year":"2020","journal-title":"Ann Oncol."},{"issue":"Supplement 1","key":"10.1002\/14651858.CD007929.pub4-BIB0058|cit58","first-page":"93","article-title":"Phase III PAOLA-1\/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV","volume":"43","author":"De Gregorio","year":"2020","journal-title":"Oncology Resarch and Treatment"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0059|cit59","unstructured":"Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab EU Clinical Trials register 2016"},{"issue":"Supplement 9","key":"10.1002\/14651858.CD007929.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"IX191","DOI":"10.1093\/annonc\/mdz446.009","article-title":"Phase III PAOLA-1\/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev","volume":"30","author":"Fujiwara","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD007929.pub4-BIB0061|cit61","first-page":"A10","article-title":"Phase III PAOLA-1\/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab","volume":"29","author":"Harter","year":"2019","journal-title":"International Journal of Gynecological Cancer\u00a0"},{"issue":"15_suppl","key":"10.1002\/14651858.CD007929.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1200\/JCO.2020.38.15_suppl.6039","article-title":"Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial","volume":"38","author":"Lorusso","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"suppl_4","key":"10.1002\/14651858.CD007929.pub4-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"S1163","DOI":"10.1016\/annonc\/annonc325","article-title":"Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"31","author":"Martin","year":"2020","journal-title":"Annals of Oncology"},{"issue":"25","key":"10.1002\/14651858.CD007929.pub4-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"New England ournal of Medicine"},{"issue":"15_suppl","key":"10.1002\/14651858.CD007929.pub4-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5607","article-title":"PAOLA-1: an ENGOT\/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab","volume":"34","author":"Ray-Coquard","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"10.1002\/14651858.CD007929.pub4-BIB0066|cit66","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS5605","article-title":"PAOLA-1: an ENGOT\/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab","volume":"34","author":"Ray-Coquard","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD007929.pub4-BIB0067|cit67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS5605","article-title":"PAOLA-1: an ENGOT\/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab","volume":"35","author":"Ray-Coquard","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"suppl_5","key":"10.1002\/14651858.CD007929.pub4-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","article-title":"Phase III PAOLA-1\/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev","volume":"30","author":"Ray-Coquard","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0069|cit69","unstructured":"Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance UMIN Clinical Trials Registry 2015"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0070|cit70","doi-asserted-by":"crossref","unstructured":"Gonzalez A Mirza MR Vergote I Li Y Hazard S Clark R A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study Annals of Oncology 2018 viii335 viii336","DOI":"10.1093\/annonc\/mdy285.150"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0071|cit71","doi-asserted-by":"crossref","unstructured":"Gonzalez A Moore KN Mirza MR Vergote IB Pothuri B Oza AM A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy Gynecologic Oncology 2017 98\u00a0","DOI":"10.1016\/j.ygyno.2017.03.231"},{"issue":"25","key":"10.1002\/14651858.CD007929.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0073|cit73","unstructured":"Gonzalez Martin A Rojas LA Braly P Barter J O'Malley DM Oza A The engot-ov26\/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy International Journal of Gynecological Cancer 2017 1510"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0074|cit74","first-page":"1510","article-title":"The engot-ov26\/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy","volume":"27","author":"Gonzalez Martin","year":"2017","journal-title":"International Journal of Gynecolical Cancer"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0075|cit75","doi-asserted-by":"crossref","unstructured":"Gonzalez Martin A Rojas LA Braly PS Barter J O'Malley DM Oza AM A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy Annals of Oncology 2017 V351","DOI":"10.1093\/annonc\/mdx372.057"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0076|cit76","doi-asserted-by":"crossref","unstructured":"A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy Journal of Clinical Oncology 2016 TPS5606 TPS5606 10.1200\/JCO.2016.34.15_suppl.TPS5606","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5606"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD007929.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1016\/j.annonc.2020.08.949","article-title":"Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"Conference: ESM","author":"Pothuri","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Banerjee S Moore KN Colombo N \u00a0Scambia G Oaknin A Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f\/u) from SOLO1 Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613 2020","DOI":"10.1016\/j.annonc.2020.08.950"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD007929.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"S613","DOI":"10.1016\/j.annonc.2020.08.950","article-title":"Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f\/u) from SOLO1","volume":"Conference: ESM","author":"Banerjee","year":"2020","journal-title":"Annals of Oncology"},{"issue":"Supplement 15","key":"10.1002\/14651858.CD007929.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1200\/JCO.2019.37.15_suppl.5539","article-title":"Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial","volume":"37","author":"Colombo","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"30","key":"10.1002\/14651858.CD007929.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1200\/JCO.20.00799","article-title":"Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial","volume":"38","author":"DiSilvestro","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0082|cit82","unstructured":"DiSilvestro P Moore K A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01844986 2013"},{"issue":"Supplement 8","key":"10.1002\/14651858.CD007929.pub4-BIB0083|cit83","first-page":"VIII727","article-title":"Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1\/2 mutation (BRCAm): phase III SOLO1 trial","volume":"29","author":"Friedlander","year":"2018","journal-title":"Annals of Oncology"},{"issue":"Supplement 15","key":"10.1002\/14651858.CD007929.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1200\/JCO.2019.37.15_suppl.5551","article-title":"Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial","volume":"37","author":"Friedlander","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0085|cit85","first-page":"ix77","article-title":"Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy","volume":"30","author":"Friedlander","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Supplement 5","key":"10.1002\/14651858.CD007929.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"V405","DOI":"10.1093\/annonc\/mdz250.004","article-title":"Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)","volume":"30","author":"Friedlander","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Supplement 9","key":"10.1002\/14651858.CD007929.pub4-BIB0087|cit87","first-page":"ix77","article-title":"Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)","volume":"30","author":"Friedlander","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Supplement 15","key":"10.1002\/14651858.CD007929.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1200\/JCO.2019.37.15_suppl.5541","article-title":"Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial","volume":"Conference: 201","author":"Mathews","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1002\/14651858.CD007929.pub4-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0090|cit90","doi-asserted-by":"crossref","unstructured":"Moore K Colombo N Scambia G Oaknin A Friedlander M Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29 2019 A14 5","DOI":"10.1136\/ijgc-2019-ESGO.17"},{"issue":"Supplement 8","key":"10.1002\/14651858.CD007929.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"viii727","DOI":"10.1093\/annonc\/mdy424.041","article-title":"Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1\/2 mutation (BRCAm): phase III SOLO1 trial","volume":"Conference: 43r","author":"Moore","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0092|cit92","doi-asserted-by":"crossref","unstructured":"Moore KN DiSilvestro P Lowe ES Garnett S Pujade-Lauraine E SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1\/2 mutation (BRCAm). Journal of Clinical Oncology (Meeting Abstracts) TPS5616","DOI":"10.1200\/jco.2014.32.15_suppl.tps5616"},{"issue":"Supplement 5","key":"10.1002\/14651858.CD007929.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"v405","DOI":"10.1093\/annonc\/mdz250.003","article-title":"Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial","volume":"30","author":"Oaknin","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Supplement 9","key":"10.1002\/14651858.CD007929.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"ix79.","DOI":"10.1093\/annonc\/mdz426.006","article-title":"Olaparib maintenance therapy in patients (pts) with a BRCA1 and\/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort","volume":"30","author":"Wu","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Supplement 15","key":"10.1002\/14651858.CD007929.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1200\/JCO.2019.37.15_suppl.5554","article-title":"Olaparib maintenance therapy in patients (pts) with a BRCA1 and\/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort","volume":"37","author":"Wu","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD007929.pub4-BIB0096|cit96","first-page":"suppl, 6070","article-title":"Patterns of progression and subsequent management of patients with BRCA1\/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2\/ENGOT Ov-21 trial (NCT01874353)","volume":"Conference: 202","author":"Berton","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Berton-Rigaud D Asher R Vidal L Pautier P Efficacy of subsequent chemotherapy for patients with BRCA1\/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2\/ENGOT Ov-21 trial Annals of Oncology 2020 S615","DOI":"10.1016\/j.annonc.2020.08.952"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD007929.pub4-BIB0098|cit98","first-page":"1941","article-title":"Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC)","volume":"[Conference: 20","author":"Friedlander","year":"2017","journal-title":"International Journal of Gynecological Cancer"},{"issue":"8","key":"10.1002\/14651858.CD007929.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(18)30343-7","article-title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","volume":"19","author":"Friedlander","year":"2018","journal-title":"Lancet Oncology"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD007929.pub4-BIB0100|cit100","first-page":"13","article-title":"Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)","volume":"[Conference: 20","author":"Friedlander","year":"2017","journal-title":"International Journal of Gynecological Cancer."},{"issue":"[Conference: an","key":"10.1002\/14651858.CD007929.pub4-BIB0101|cit101","first-page":"51","article-title":"Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study","volume":"13","author":"Friedlander","year":"2017","journal-title":"Asia-Pacific Journal of Clinical Oncology.\u00a0"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0102|cit102","first-page":"51","article-title":"Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study","volume":"[Conference: An","author":"Friedlander","year":"2017","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"15 Supplement 1","key":"10.1002\/14651858.CD007929.pub4-BIB0103|cit103","first-page":"13","article-title":"Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)","volume":"[Conference: 20","author":"Gourley","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD007929.pub4-BIB0104|cit104","first-page":"93","article-title":"Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2\/AGO-OVAR2.23 trial","volume":"78","author":"Hanker","year":"2018","journal-title":"Geburtshilfe und frauenheilkunde"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0105|cit105","doi-asserted-by":"crossref","unstructured":"Hanker LC Heitz F Park-Simon TW Gropp-Meier M Ataseven B Pujade-Lauraine E Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2\/AGO-OVAR2.23 trial, AGO Study Group & GINECO Geburtshilfe und Frauenheilkunde 2018 10.1055\/s-0038-1671027","DOI":"10.1055\/s-0038-1671027"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD007929.pub4-BIB0106|cit106","first-page":"88","article-title":"Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III","volume":"[Conference: 33","author":"Hasenburg","year":"2018","journal-title":"Oncology Research and Treatment"},{"issue":"Supplement 8","key":"10.1002\/14651858.CD007929.pub4-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"viii340","DOI":"10.1093\/annonc\/mdy285.160","article-title":"Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial","volume":"Conference: 43r","author":"Korach","year":"2018","journal-title":"Annals of Oncology"},{"issue":"15 Supplement 1","key":"10.1002\/14651858.CD007929.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1200\/JCO.2017.35.15_suppl.5518","article-title":"Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial","volume":"Conference: 201","author":"Ledermann","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD007929.pub4-BIB0109|cit109","first-page":"49","article-title":"Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort","volume":"Conference: 17t","author":"Liu","year":"2018","journal-title":"International Journal of Gynecological"},{"issue":"15 Suppl. 1","key":"10.1002\/14651858.CD007929.pub4-BIB0110|cit110","first-page":"5505","article-title":"Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC)","volume":"Conference: 201","author":"Matulonis","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD007929.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/cncr.29995","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy","volume":"122","author":"Matulonis","year":"2016","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0112|cit112","first-page":"8","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy","volume":"137","author":"Matulonis","year":"2015","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0113|cit113","doi-asserted-by":"crossref","unstructured":"Moore KN DiSilvestro P Lowe ES Garnett S Pujade-Lauraine E SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1\/2 mutation (BRCAm). Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616 2014","DOI":"10.1200\/jco.2014.32.15_suppl.tps5616"},{"issue":"Supplement 5","key":"10.1002\/14651858.CD007929.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"v344","DOI":"10.1093\/annonc\/mdx372.036","article-title":"Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21)","volume":"Conference: 42n","author":"Oza","year":"2017","journal-title":"Annals of Oncology"},{"issue":"Supplement 5","key":"10.1002\/14651858.CD007929.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"v331","DOI":"10.1093\/annonc\/mdx372.002","article-title":"Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21)","volume":"Conference: 42n","author":"Penson","year":"2017","journal-title":"Annals of Oncology"},{"issue":"15","key":"10.1002\/14651858.CD007929.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1200\/JCO.2020.38.15_suppl.6002","article-title":"Final overall survival (OS) results from SOLO2\/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation","volume":"Conference: 202","author":"Poveda","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD007929.pub4-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"SOLO2\/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncology"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD007929.pub4-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ygyno.2017.03.505","article-title":"Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study","volume":"Conference: 48t","author":"Pujade-Lauraine","year":"2017","journal-title":"Gynecologic Oncology"},{"issue":"9","key":"10.1002\/14651858.CD007929.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0120|cit120","unstructured":"Pujade-Lauraine E Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy https:\/\/clinicaltrials.gov\/NCT01874353 2013"},{"issue":"15","key":"10.1002\/14651858.CD007929.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1200\/JCO.2020.38.15_suppl.6068","article-title":"Efficacy and safety of olaparib according to age in BRCA-1\/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23\/ENGOTOv21) study","volume":"Conference: 202","author":"Trillsch","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"15_supp","key":"10.1002\/14651858.CD007929.pub4-BIB0122|cit122","article-title":"SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI\/2 mutation (gBRCAm)","volume":"\u00a034","author":"Lowe","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1\/2Mutation (SOLO3): A Randomized Phase III Trial","volume":"38","author":"\u00a0Valencia","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_supp","key":"10.1002\/14651858.CD007929.pub4-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1200\/JCO.2019.37.15_suppl.5506","article-title":"Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial","volume":"37","author":"Penson","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD007929.pub4-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"British Journal of Cancer."},{"issue":"8","key":"10.1002\/14651858.CD007929.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncology"},{"issue":"(10)","key":"10.1002\/14651858.CD007929.pub4-BIB0127|cit127","first-page":"594","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"69","author":"Ledermann","year":"2015","journal-title":"Obstetrical & Gynecological Survey"},{"issue":"10","key":"10.1002\/14651858.CD007929.pub4-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/OGX.0000000000000107","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"69","author":"Ledermann","year":"2015","journal-title":"Obstetrical & Gynecological Survey"},{"issue":"15","key":"10.1002\/14651858.CD007929.pub4-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0130|cit130","doi-asserted-by":"crossref","unstructured":"Ledermann J Harter P Gourley C Friedlander M Vergote I Rustin G Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) International Journal of Gynecological Cancer 2011","DOI":"10.1200\/jco.2011.29.15_suppl.5003"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0131|cit131","unstructured":"Ledermann J Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer http:\/\/clinicaltrials.gov\/show\/NCT00753545"},{"issue":"11","key":"10.1002\/14651858.CD007929.pub4-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1002\/14651858.CD007929.pub4-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/bjc.2016.348","article-title":"Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer","volume":"115","author":"Ledermann","year":"2016","journal-title":"British Journal of Cancer"},{"issue":"Supplement 15","key":"10.1002\/14651858.CD007929.pub4-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2016.34.15_suppl.5501","article-title":"Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis","volume":"Conference: 201","author":"Ledermann","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0135|cit135","doi-asserted-by":"crossref","unstructured":"Ledermann JA Harter P Gourley C Friedlander M Vergote IB Rustin GJ Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) Journal of Clinical Ocology 2011","DOI":"10.1200\/jco.2011.29.15_suppl.5003"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0136|cit136","doi-asserted-by":"crossref","unstructured":"Matulonis UA Harter P Gourley C Friedlander M Vergote IB Rustin GJ Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5 2014","DOI":"10.1016\/j.ygyno.2014.03.152"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD007929.pub4-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1016\/j.annonc.2020.08.948","article-title":"Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint)","volume":"31","author":"Cella","year":"2020","journal-title":"Annals of Oncology"},{"issue":"25","key":"10.1002\/14651858.CD007929.pub4-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0139|cit139","unstructured":"Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer EU Clinical Trials register 2015"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0140|cit140","unstructured":"Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA) Clinical Trial Gov register 2015"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0141|cit141","unstructured":"Platine, Avastin and OLAparib in 1st Line (PAOLA-1) Clinical Trials Gov register 2015"},{"issue":"4","key":"10.1002\/14651858.CD007929.pub4-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000486418","article-title":"PARP (Poly(ADP-Ribose) Polymerase) inhibitors in platinum-sensitive recurrent ovarian cancer: A meta-analysis of randomized controlled trials","volume":"41","author":"Al Hadidi","year":"2018","journal-title":"Oncology Research Treatments"},{"issue":"15S","key":"10.1002\/14651858.CD007929.pub4-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1200\/jco.2009.27.15_suppl.5500","article-title":"Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer","volume":"27","author":"Audeh","year":"2009","journal-title":"Journal of Clinical Oncology (Meeting Abstracts)"},{"issue":"9737","key":"10.1002\/14651858.CD007929.pub4-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0145|cit145","doi-asserted-by":"crossref","unstructured":"Colombo N Nicoletto MO Benedetti Panici P Tognon G Bologna A Lissoni AA BAROCCO: a randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC) Conference: 44th ESMO Congress. Spain. 30 2019 v896","DOI":"10.1093\/annonc\/mdz394.055"},{"issue":"Supplement 8","key":"10.1002\/14651858.CD007929.pub4-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"viii357","DOI":"10.1093\/annonc\/mdy285.209","article-title":"BAROCCO: a randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum-resistant ovarian cancer","volume":"29","author":"Colombo","year":"2018","journal-title":"Annals of Oncology"},{"issue":"Supplement 8","key":"10.1002\/14651858.CD007929.pub4-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"viii357","DOI":"10.1093\/annonc\/mdy285.209","article-title":"BAROCCO: a randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer","volume":"Conference: 43r","author":"Colombo","year":"2018","journal-title":"Annals of oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0148|cit148","unstructured":"Best approach in recurrent-ovarian-cancer-with cediranib-olaparib https:\/\/clinicaltrials.gov\/show\/nct03314740 2017"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0149|cit149","unstructured":"Japanese Society of Medical Oncology 2016 Annual Meeting Ann Oncol. 2016"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0150|cit150","doi-asserted-by":"crossref","unstructured":"Coleman RL Sill M Aghajanian C Gray HJ Tewari KS Rubin SC A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - A Gynecologic Oncology Group study Gynecologic Oncology 2014 56 57","DOI":"10.1016\/j.ygyno.2014.03.156"},{"issue":"15_suppl","key":"10.1002\/14651858.CD007929.pub4-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1200\/JCO.2017.35.15_suppl.5560","article-title":"The successful phase 3 niraparib ENGOT-OV16\/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC)","volume":"35","author":"Del Campo","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0152|cit152","doi-asserted-by":"crossref","unstructured":"Dockery L Tew W Moore K Ding K Tolerance and toxicity of the PARP inhibitor olaparib in older women with ovarian cancer Gynecologic Oncology 2017 197 8 10.1016\/j.ygyno.2017.07.029","DOI":"10.1016\/j.ygyno.2017.07.029"},{"issue":"3","key":"10.1002\/14651858.CD007929.pub4-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ygyno.2017.10.007","article-title":"Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer","volume":"147","author":"Dockery","year":"2017","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0154|cit154","unstructured":"A multicentre, open-label, three-arm randomised Phase II trial assessing the safety and efficacy of the HSP90 inhibitor Ganetespib in combination with Carboplatin followed by maintenance treatment with Niraparib versus Ganetespib plus Carboplatin followed by Ganetespib and Niraparib versus Carboplatin in combination with standard chemotherapy followed by Niraparib maintenance treatment in platinum-sensitive ovarian cancer patients Http:\/\/www.who.int\/trialsearch\/trial2.aspx? Trialid=euctr2017-004058-40-be\u00a0 2018"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0155|cit155","unstructured":"Study to evaluate the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib in patients with previously untreated advanced ovarian cancer International Clinical Trials Registry Platform (ICTRP) 2018"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0156|cit156","doi-asserted-by":"crossref","unstructured":"Fisher M Guy H Walder L Estimating the mean progression-free survival of niraparib, olaparib and rucaparib compared to routine surveillance for the maintenance treatment of adult patients with recurrent ovarian cancer without a BRCA mutation Value in Health 2018 S21","DOI":"10.1016\/j.jval.2018.09.121"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD007929.pub4-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/jco.2006.24.18_suppl.3022","article-title":"Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours","volume":"24","author":"Fong","year":"2006","journal-title":"Journal of Clinical Oncology (Meeting Abstracts)"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007929.pub4-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1200\/jco.2008.26.15_suppl.5510","article-title":"AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study","volume":"26","author":"Fong","year":"2008","journal-title":"Journal of Clinical Oncology (Meeting Abstracts)"},{"issue":"2","key":"10.1002\/14651858.CD007929.pub4-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD007929.pub4-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer:a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncology"},{"issue":"15_suppl (2020","key":"10.1002\/14651858.CD007929.pub4-BIB0161|cit161","article-title":"Population-adjusted indirect treatment comparison (PAITC) of maintenance PARP inhibitor (PARPi) with or without bevacizumab versus bevacizumab in women with newly diagnosed ovarian cancer (OC)","volume":"38","author":"Hettle","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0162|cit162","doi-asserted-by":"crossref","unstructured":"Kristeleit RS Shapira-Frommer R Oaknin A Balmana J Ray-Coquard IL Domchek S Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2) Annals of Oncology 2016 10.1093\/annonc\/mdw374.3","DOI":"10.1093\/annonc\/mdw374.03"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0163|cit163","doi-asserted-by":"crossref","unstructured":"Kristeleit RS Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): analysis of pooled data from study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2) Clinical Advances in Hematology & Oncology 2016 11 2","DOI":"10.1093\/annonc\/mdw374.03"},{"issue":"Supplement 5 [4","key":"10.1002\/14651858.CD007929.pub4-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"v409","DOI":"10.1093\/annonc\/mdz250.010","article-title":"Integrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings","volume":"30","author":"Kristeleit","year":"2019","journal-title":"Annals of Oncology"},{"issue":"suppl_5","key":"10.1002\/14651858.CD007929.pub4-BIB0165|cit165","first-page":"abstr no. 5535","article-title":"Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648)","volume":"32","author":"Liu","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement 5","key":"10.1002\/14651858.CD007929.pub4-BIB0166|cit166","first-page":"v432","article-title":"An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION","volume":"30","year":"2019","journal-title":"Annals of Oncology"},{"issue":"15","key":"10.1002\/14651858.CD007929.pub4-BIB0167|cit167","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","article-title":"Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization","volume":"23","author":"Lheureux","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0168|cit168","doi-asserted-by":"crossref","unstructured":"Liu J Barry WT Birrer MJ Buckanovich RJ Fleming GF A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer Journal of Clinical Oncology 2014 Abstract no LBA550","DOI":"10.1200\/jco.2014.32.15_suppl.lba5500"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0169|cit169","doi-asserted-by":"crossref","unstructured":"Liu AY Cohen JG Walsh CS Holschneider CH Sinno AK A cost-effectiveness analysis of three PARP inhibitors for maintenance therapy in platinum-sensitive recurrent ovarian cancer Gynecologic oncology. Conference: 2016 annual meeting of the western association of gynecologic oncologists, WAGO 2016. United states 2017 196 10.1016\/j.ygyno.2017.07.025","DOI":"10.1016\/j.ygyno.2017.07.025"},{"issue":"11","key":"10.1002\/14651858.CD007929.pub4-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncology"},{"issue":"SUPPL. 1","key":"10.1002\/14651858.CD007929.pub4-BIB0171|cit171","first-page":"8","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: a multi-study sub-analysis","volume":"137","author":"Matulonis","year":"2015","journal-title":"Gynecologic Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007929.pub4-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: a multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Annals of Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007929.pub4-BIB0173|cit173","first-page":"iv305","article-title":"Preliminary results of ARIEL2, a phase 2 open-label study to identify ovarian cancer patients likely to respond to rucaparib","volume":"25","author":"McNeish","year":"2014","journal-title":"Annals of Oncology"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD007929.pub4-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2019.04.630","article-title":"Effects of PARP inhibitors therapy on the PFS and OS in platinum-sensitive recurrent ovarian cancer: a meta-analysis of randomized controlled trials","volume":"Conference: 50t","author":"Min","year":"2019","journal-title":"Gynecologic Oncology"},{"issue":"15_suppl","key":"10.1002\/14651858.CD007929.pub4-BIB0175|cit175","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.tps5607","article-title":"ENGOT-OV24-NSGO\/ AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.","volume":"33","author":"Mirza","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement 3","key":"10.1002\/14651858.CD007929.pub4-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jval.2018.09.090","article-title":"A time without symptoms or toxicity analysis of niraparib compared with routine surveillance in the maintenance treatment of patients with recurrent ovarian cancer","volume":"Conference: ISP","author":"Mirza","year":"2018","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0177|cit177","doi-asserted-by":"crossref","unstructured":"Moore KN Agarwal S Patel MR Burris HA Martell RE Food effect substudy of a phase 3 randomized double-blind trial of maintenance with niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor versus placebo in patients with platinum-sensitive ovarian cancer. Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts. e16531","DOI":"10.1200\/jco.2014.32.15_suppl.e16531"},{"issue":"5","key":"10.1002\/14651858.CD007929.pub4-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0179|cit179","unstructured":"Study of tremelimumab alone or combined with olaparib for patients with persistent EOC (epithelial ovarian, fallopian tube or primary peritoneal carcinoma Clinical Trials Gov register\u00a0 2015"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0180|cit180","unstructured":"A study evaluating talazoparib in relapsed ovarian, fallopian tube, and peritoneal cancer) Clinical Trials Gov register 2016"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0181|cit181","unstructured":"Adavosertib with or without olaparib in treating participants with recurrent ovarian, primary peritoneal, or fallopian tube cancer Clinical Trials Gov register 2018"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0182|cit182","unstructured":"Study of chemotherapy with pembrolizumab (MK-3475) followed by maintenance with olaparib (MK-7339) for the first-line treatment of women with BRCA non-mutated advanced epithelial ovarian cancer (EOC) (MK-7339-001\/ENGOT-ov43\/KEYLYNK-001) Clinical Trials Gov register 2018"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0183|cit183","unstructured":"European trial on enhanced DNA repair inhibition in ovarian cancer Clinical Trials Gov register 2018"},{"issue":"15_suppl [2020","key":"10.1002\/14651858.CD007929.pub4-BIB0184|cit184","article-title":"The incidence of myelodysplastic syndrome in patients receiving poly-ADP ribose polymerase inhibitors for treatment of solid tumors: a meta-analysis","volume":"38","author":"Nitecki","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0185|cit185","doi-asserted-by":"crossref","unstructured":"Orbegoso Aguilar CM Dumas L Davies E Gore M George A Banerjee S Olaparib maintenance treatment, the Royal Marsden experience Annals of Oncology 2018","DOI":"10.1093\/annonc\/mdy436.020"},{"issue":"2","key":"10.1002\/14651858.CD007929.pub4-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecologic Oncology"},{"issue":"9","key":"10.1002\/14651858.CD007929.pub4-BIB0187|cit187","article-title":"Maintenance therapy in ovarian cancer with targeted agents improves PFS and OS: a systematic review and meta-analysis","volume":"10","author":"Qian","year":"2015","journal-title":"PLOS One EMT"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0188|cit188","doi-asserted-by":"crossref","unstructured":"Rimel BJ Secord AA Geller MA Miller DS Cloven N Fleming GF Safety and efficacy results of retreatment with a PARP inhibitor monotherapy in late-line recurrent ovarian cancer: results From a Subset of the QUADRA Trial Gynecologic Oncology 2020","DOI":"10.1016\/j.ygyno.2019.11.045"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"102040","DOI":"10.1016\/j.ctrv.2020.102040","article-title":"Incorporating Parp-inhibitors in primary and recurrent ovarian cancer: a meta-analysis of 12 phase II\/III randomized controlled trials","volume":"87","author":"Ruscito","year":"2020","journal-title":"Cancer Treatment Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007929.pub4-BIB0190|cit190","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045%2816%2930559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"LancetOoncology"},{"issue":"Supplement 8","key":"10.1002\/14651858.CD007929.pub4-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"viii627","DOI":"10.1093\/annonc\/mdy300.077","article-title":"Risk of health-related quality of life events and pulmonary toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance","volume":"Conference: 43r","author":"Thein","year":"2018","journal-title":"Annals of Oncology"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD007929.pub4-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/jco.2007.25.18_suppl.3529","article-title":"First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1\/2 mutation carriers","volume":"25","author":"Yap","year":"2007","journal-title":"Journal of Clinical Oncology (Meeting Abstracts)"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0193|cit193","unstructured":"Kristeleit RS Lorusso D Oaknin A Safra T Swisher EM Bondarenko IM Ariel4: an international, randomised phase 3 study of rucaparib vs chemotherapy in BRCA1- or BRCA2-mutated, relapsed ovarian cancer (OC) International journal of gynecological cancer. Conference: 20th international meeting of the european society of gynaecological oncology. Austria 2017 1555 10.1097\/01.IGC.0000527296.86225.87"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0194|cit194","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1097\/01.IGC.0000527296.86225.87","article-title":"Ariel4: an international, randomised phase 3 study of rucaparib vs chemotherapy in BRCA1- or BRCA2-mutated, relapsed ovarian cancer (OC)","volume":"27","author":"Kristeleit","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl_5","key":"10.1002\/14651858.CD007929.pub4-BIB0195|cit195","doi-asserted-by":"publisher","first-page":"v330","DOI":"10.1093\/annonc\/mdx372","article-title":"ARIEL4: an international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCAmutated, relapsed, high-grade ovarian cancer","volume":"28","author":"Kristeleit","year":"2017","journal-title":"Annals of Oncolgy"},{"issue":"Supplement 5","key":"10.1002\/14651858.CD007929.pub4-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"v352","DOI":"10.1093\/annonc\/mdx372.059","article-title":"ARIEL4: an international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCAmutated, relapsed, high-grade ovarian cancer","volume":"28","author":"Kristeleit","year":"2017","journal-title":"Annals of Oncology"},{"issue":"15_suppl","key":"10.1002\/14651858.CD007929.pub4-BIB0197|cit197","article-title":"ARIEL4: an international, multicenter randomized phase 3 study of the PARP inhibitor rucaparib vs chemotherapy in germline or somatic BRCA1-or BRCA2-mutated, relapsed, high-grade ovarian carcinoma","volume":"35","author":"Oza","year":"2017","journal-title":"Journal of Clinicsl Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0198|cit198","doi-asserted-by":"crossref","unstructured":"Christopoulou A Marme F Oaknin A Lorusso D Safra T Lindahl G Athena (GOG-3020\/ENGOT-OV45; EUDRACT 2017- 004557-17; NCT03522246): a randomised, double-blind, placebo-controlled, phase 3 study of the poly(ADP-RIBOSE) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-base International Journal of Gynecological Cancer 2019 A130 131 10.1136\/ijgc-2019-ESGO.179","DOI":"10.26226\/morressier.5d43ffa5baa7e4c58300ac70"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0199|cit199","doi-asserted-by":"crossref","unstructured":"Fujiwara K Chou HH Kim JW Tan DS Tamura K Katsumata N ATHENA (GOG-3020\/ENGOT-ov45): a randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer Annals of Oncology 2019 ix88 9 10.1093\/annonc\/mdz426.038","DOI":"10.1093\/annonc\/mdz426.038"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0200|cit200","unstructured":"Goh JC Baron-Hay S Bonaventura T Buck M Dean A Friedlander M ATHENA (GOG-3020\/ENGOT-ov45): a randomised, double-blind, placebo-controlled, phase 3 study of rucaparib+ nivolumab following front-line platinum-based chemotherapy in ovarian cancer Asia-Pacific Journal of Clinical Oncology 2018 196"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0201|cit201","unstructured":"Monk BJ Coleman RL Fujiwara K Oza AM Westin SN O'Malley DM Athena (gog-3020\/ENGOT-ov45): a randomised, double-blind, placebo-controlled, phase 3 study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer International journal of Gynecological Cancer 2018 1019 20"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0202|cit202","doi-asserted-by":"crossref","unstructured":"Westin SN Kristeleit RS Coleman RL Fujiwara K Oza AM O'Malley DM ATHENA (GOG-3020\/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer Cancer Research 2019","DOI":"10.1158\/1538-7445.AM2019-CT158"},{"issue":"11","key":"10.1002\/14651858.CD007929.pub4-BIB0203|cit203","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1136\/ijgc-2020-001694","article-title":"DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymeras","volume":"30","author":"McMullen","year":"2020","journal-title":"International Journal of Gynelogical Cancer."},{"issue":"15_supp","key":"10.1002\/14651858.CD007929.pub4-BIB0204|cit204","article-title":"DUO-O: a randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients","volume":"37","author":"Harter","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"15_supp","key":"10.1002\/14651858.CD007929.pub4-BIB0205|cit205","article-title":"DUO-E\/GOG-3041\/ENGOT-EN10: a randomized phase III trial of firstline carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd)","volume":"38","author":"Westin","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement 9","key":"10.1002\/14651858.CD007929.pub4-BIB0206|cit206","doi-asserted-by":"publisher","first-page":"IX89","DOI":"10.1093\/annonc\/mdz426.039","article-title":"ENGOT-OV43\/KEYLYNK-001: a phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer","volume":"30","author":"Fujiwara","year":"2019","journal-title":"Annals of \u00a0Oncology"},{"issue":"Supplement 15","key":"10.1002\/14651858.CD007929.pub4-BIB0207|cit207","article-title":"ENGOT-OV43\/KEYLYNK-001: a phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer","volume":"37","author":"Vergote","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"15_supp","key":"10.1002\/14651858.CD007929.pub4-BIB0208|cit208","article-title":"ENGOT-OV44\/FIRST study: a randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3\/4 non-mucinous epithelia","volume":"37","author":"Hardy-Bessard","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0209|cit209","unstructured":"Study evaluating the efficacy of maintenance olaparib and cediranib or olaparib alone in ovarian cancer patients Clinical Trial Gov register 2017"},{"issue":"8_suppl","key":"10.1002\/14651858.CD007929.pub4-BIB0210|cit210","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.8_suppl.TPS9","article-title":"JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer","volume":"37","author":"Eskander","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0211|cit211","unstructured":"Avelumab and talazoparib in Untreated advanced ovarian cancer (JAVELIN OVARIAN PARP 100) Clinical Trials Gov register 2018"},{"issue":"7","key":"10.1002\/14651858.CD007929.pub4-BIB0212|cit212","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0213|cit213","unstructured":"Olaparib maintenance treatment versus placebo in patients with PSR ovarian cancer who are in CR or PR to platinum-based chemotherapy and whose tumours carry sBRCAm or HRR-associated genes mutations Clinical Trials Gov register 2015"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0214|cit214","unstructured":"A study of olaparib prior to surgery and chemotherapy in ovarian, primary peritoneal, and fallopian tube cancer Clinical Trials Gov register 2015"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0215|cit215","unstructured":"Cediranib maleate and olaparib or standard chemotherapy in treating patients with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer Clinical Trials Gov register 2015"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0216|cit216","unstructured":"A study to evaluate the effectiveness and tolerability of a second maintenance treatment in participants with ovarian cancer, who have previously received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) treatment Clinical Trials Gov register 2020"},{"issue":"15_suppl","key":"10.1002\/14651858.CD007929.pub4-BIB0217|cit217","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS5608","article-title":"Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): the NEO trial","volume":"35","author":"Kanjanapan","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0218|cit218","doi-asserted-by":"crossref","unstructured":"Braicu E I Wimberger P Richter R Keller M Krabisch P Deryal M NOGGO Ov-42\/MAMOC: rucaparib maintenance after bevacizumab maintenance following carboplatin-based first line-chemotherapy in ovarian cancer patients Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38 2020","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS6102"},{"issue":"suppl_5","key":"10.1002\/14651858.CD007929.pub4-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"v403","DOI":"10.1093\/annonc\/mdz250","article-title":"A prospective evaluation of tolerability of niraparib dosing based on baseline body weight (BW) and platelet (plt) count: blinded pooled interim safety data from the NORA study","volume":"30","author":"Wu","year":"2019","journal-title":"Annls of Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0220|cit220","unstructured":"Trial of different drug and treatment combinations for patients with inherited genetic changes who are considering further therapy to treat their ovarian cancer ISRCTN registry 2018"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0221|cit221","doi-asserted-by":"crossref","unstructured":"Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol BMJ Open 11 1 e041463 10.1136\/bmjopen-2020-041463","DOI":"10.1136\/bmjopen-2020-041463"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0222|cit222","unstructured":"Olaparib +\/- cediranib or chemotherapy in patients with BRCA mutated platinum-resistant ovarian cancer Clinical Trials Gov register 2017"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0223|cit223","doi-asserted-by":"publisher","first-page":"v352","DOI":"10.1093\/annonc\/mdx372.060","article-title":"OCTOVA: a randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinum-resistant ovarian cancer","volume":"28","author":"Nicum","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0224|cit224","doi-asserted-by":"crossref","unstructured":"Nicum S Strauss VY McGregor N McNeish I Roux R Hall M CNO - CN-01438443 OCTOVA: a randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinumresistant ovarian cancer Annals of Oncology 2017","DOI":"10.1093\/annonc\/mdx372.060"},{"issue":"Suppl_5 [2020 A","key":"10.1002\/14651858.CD007929.pub4-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"V352","DOI":"10.1093\/annonc\/mdx372.060","article-title":"OCTOVA: a randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinum-resistant ovarian cancer","volume":"28","author":"Nicum","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0226|cit226","unstructured":"Retreatment with olaparib in patients with epithelian ovarian cancer EU Clinical Trials register 2017"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0227|cit227","unstructured":"A study to examine olaparib maintenance retreatment in patients with epithelial ovarian cancer Clinical Trials Gov register 2017"},{"issue":"Supplement 5","key":"10.1002\/14651858.CD007929.pub4-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"V351","DOI":"10.1093\/annonc\/mdx372.058","article-title":"OReO\/ENGOT Ov-38: a phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer","volume":"28","author":"Pujade-Lauraine","year":"2017","journal-title":"Ann Oncol."},{"issue":"Supplement 4","key":"10.1002\/14651858.CD007929.pub4-BIB0229|cit229","first-page":"1634","article-title":"OREO phase IIIB trial: olaparib maintenance retreatment in platinum-sensitive, relapsed epithelial ovarian cancer patients previously treated with a parp inhibitor (PARPI)","volume":"27","author":"Pujade-Lauraine","year":"2017","journal-title":"International Journal of Gynecolgy Cancer"},{"issue":"11","key":"10.1002\/14651858.CD007929.pub4-BIB0230|cit230","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.3390\/ijms21113805","article-title":"Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: A network meta-analysis","volume":"21","author":"Bartoletti","year":"2020","journal-title":"International Journal of Molecular Science"},{"issue":"7035","key":"10.1002\/14651858.CD007929.pub4-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"6","key":"10.1002\/14651858.CD007929.pub4-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/nar\/gkl108","article-title":"Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair","volume":"34","author":"Bryant","year":"2006","journal-title":"Nucleic Acids Research"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0233|cit233","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/em.22087","article-title":"Mechanisms of DNA damage, repair, and mutagenesis","volume":"58","author":"Chatterjee","year":"2017","journal-title":"Environmental and Molecular \u00a0Mutagenesis"},{"issue":"2","key":"10.1002\/14651858.CD007929.pub4-BIB0234|cit234","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00404-021-06070-2","article-title":"Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis","volume":"304","author":"Cheng","year":"2021","journal-title":"Archives of \u00a0Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0235|cit235","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1056\/NEJMra0805239","article-title":"Molecular basis of metastasis","volume":"25","author":"Chiang","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD007929.pub4-BIB0236|cit236","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005343.pub6","article-title":"Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer","author":"Coleridge","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0237|cit237","unstructured":"Covidence systematic review software Veritas Health Innovation 2019"},{"issue":"4","key":"10.1002\/14651858.CD007929.pub4-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S146239940500904X","article-title":"PARP inhibitors for cancer therapy","volume":"7","author":"Curtin","year":"2005","journal-title":"Expert Reviews in Molecular Medicine"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0239|cit239","volume-title":"Systematic Reviews in Health Care: Meta-Analysis in Context","author":"Deeks","year":"2001"},{"issue":"3","key":"10.1002\/14651858.CD007929.pub4-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0241|cit241","unstructured":"EPOC Resources for review authors epoc.cochrane.org\/epoc-specific-resources-review-authors"},{"issue":"5","key":"10.1002\/14651858.CD007929.pub4-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajog.2013.04.019","article-title":"The role of the fallopian tube in the origin of ovarian cancer","volume":"209","author":"Erickson","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"7035","key":"10.1002\/14651858.CD007929.pub4-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"11","key":"10.1002\/14651858.CD007929.pub4-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/sim.4780091106","article-title":"Quality adjusted survival analysis","volume":"9","author":"Glasziou","year":"1990","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0245|cit245","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer Journal for Clinicians"},{"issue":"10","key":"10.1002\/14651858.CD007929.pub4-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1136\/ijgc-2020-001373","article-title":"Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis","volume":"30","author":"Gong","year":"2020","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0247|cit247","unstructured":"GRADEpro[Computer program on www.gradepro.org]. McMaster University 2014"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"102888","DOI":"10.1016\/j.critrevonc.2020.102888","article-title":"Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: a meta-analysis","volume":"147","author":"Gu","year":"2020","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"103145","DOI":"10.1016\/j.critrevonc.2020.103145","article-title":"Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials","volume":"157","author":"Hao","year":"2021","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"22","key":"10.1002\/14651858.CD007929.pub4-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007929.pub4-BIB0251|cit251","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ygyno.2013.11.008","article-title":"Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper","volume":"132","author":"Herzog","year":"2014","journal-title":"\u00a0Gynecologic Oncology"},{"issue":"7414","key":"10.1002\/14651858.CD007929.pub4-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0253|cit253","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD007929.pub4-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrd1718","article-title":"Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors","volume":"4","author":"Jagtap","year":"2005","journal-title":"National Reviews of Drug Discovery"},{"issue":"2","key":"10.1002\/14651858.CD007929.pub4-BIB0255|cit255","first-page":"71","article-title":"Cancer statistics","volume":"58","author":"Jemal","year":"2008","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3389\/fonc.2020.00954","article-title":"Evaluation of the efficacy and safety of PARP inhibitors in advanced-stage epithelial ovarian cancer","volume":"10","author":"Jiang","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0257|cit257","doi-asserted-by":"publisher","first-page":"Apr 29:10600280","DOI":"10.1177\/10600280211013489","article-title":"Effect of PARP inhibitors as maintenance treatment on restricted mean survival time in platinum-sensitive recurrent ovarian cancer: a systematic review and meta-analysis","volume":"Epub ahead of p","author":"Kaneko","year":"2021","journal-title":"Annals of Pharmacotherapy"},{"issue":"12","key":"10.1002\/14651858.CD007929.pub4-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","article-title":"Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis","volume":"178","author":"Kovic","year":"2018","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0259|cit259","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"European Journal of Cancer"},{"issue":"14","key":"10.1002\/14651858.CD007929.pub4-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1002\/cncr.33517","article-title":"Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis","volume":"127","author":"Lee C","year":"2021","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"23","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0262|cit262","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1120009X.2021.1884797","article-title":"Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II\/III randomized controlled trials","volume":"E pub ahead of","author":"Li","year":"2021","journal-title":"Journal of Chemotherapy"},{"issue":"3","key":"10.1002\/14651858.CD007929.pub4-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/1471-0528.16411","article-title":"PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis","volume":"128","author":"Lin","year":"2021","journal-title":"BJOG"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.2147\/DDDT.S164553","article-title":"Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials","volume":"12","author":"Liu","year":"2018","journal-title":"Drug Design, Development and Therapy"},{"issue":"6","key":"10.1002\/14651858.CD007929.pub4-BIB0265|cit265","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3390\/cancers12061607","article-title":"Overcoming platinum and PARP-Inhibitor resistance in ovarian cancer","volume":"12","author":"McMullen","year":"2020","journal-title":"Cancers"},{"issue":"10290","key":"10.1002\/14651858.CD007929.pub4-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD007929.pub4-BIB0267|cit267","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/s12885-020-06948-5","article-title":"Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review","volume":"20","author":"Mohyuddin","year":"2020","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1002\/14651858.CD007929.pub4-BIB0268|cit268","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.annonc.2021.04.023","article-title":"PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials","volume":"32","author":"Morice","year":"2021","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD007929.pub4-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0270|cit270","unstructured":"National Institute for Clinical Excellence (NICE) Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer - guidance [CG164] https:\/\/www.nice.org.uk\/Guidance\/CG164 2013 https:\/\/www.nice.org.uk\/Guidance\/CG164"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0271|cit271","unstructured":"National Institute for Health and Care Excellence (NICE)\u00a0 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy [TA598) https:\/\/www.nice.org.uk\/guidance\/ta598 2019 https:\/\/www.nice.org.uk\/guidance\/ta598\/"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0272|cit272","unstructured":"National Insitute for Health and Care Excellence Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. Technology appraisal guidance [TA611]\u00a0 https:\/\/www.nice.org.uk\/guidance\/ta611 https:\/\/www.nice.org.uk\/guidance\/ta611"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0273|cit273","unstructured":"National Insitute for Health and Care Excellence Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. Technology appraisal guidance [TA620] P https:\/\/www.nice.org.uk\/guidance\/ta620 https:\/\/www.nice.org.uk\/guidance\/ta620"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0274|cit274","unstructured":"National Institute for Health and Care Excellence (NICE) Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [TA673] https:\/\/www.nice.org.uk\/guidance\/ta673 2021 https:\/\/www.nice.org.uk\/guidance\/ta673"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0275|cit275","unstructured":"National Institute for Health and Care Excellence (NICE) Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancerTechnology appraisal guidance [TA693]\u00a0 https:\/\/www.nice.org.uk\/guidance\/ta693 https:\/\/www.nice.org.uk\/guidance\/ta693"},{"issue":"1","key":"10.1002\/14651858.CD007929.pub4-BIB0276|cit276","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jocn.2007.06.005","article-title":"Contribution of DNA repair mechanisms to determining chemotherapy response in high-grade glioma.","volume":"15","author":"Parkinson","year":"2008","journal-title":"Journal of Clinical Neuroscience"},{"issue":"24","key":"10.1002\/14651858.CD007929.pub4-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007929.pub4-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12094-008-0207-8","article-title":"Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment","volume":"10","author":"Peralta-Leal","year":"2008","journal-title":"Clinical Translations in Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0279|cit279","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/s41416-018-0312-6.","article-title":"Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts","volume":"11","author":"Berta","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0280|cit280","volume-title":"Cancer Trends in England and Wales","author":"Quinn","year":"2001"},{"issue":"5","key":"10.1002\/14651858.CD007929.pub4-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-06-2260","article-title":"Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology","volume":"13","author":"Ratnam","year":"2007","journal-title":"Clinical Cancer Research"},{"issue":"237","key":"10.1002\/14651858.CD007929.pub4-BIB0282|cit282","first-page":"1","article-title":"The role of PARP inhibitors in the treatment of gynecologic malignancies","volume":"3","author":"Reinbolt","year":"2013","journal-title":"Frontiers in Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0283|cit283","unstructured":"Review Manager (RevMan) The Nordic Cochrane Centre, The Cochrane Collaboration 2020"},{"issue":"3","key":"10.1002\/14651858.CD007929.pub4-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"American Journal of Human Genetics"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0285|cit285","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Akl E on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group Chapter 11: Completing \u2018Summary of findings\u2019 tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0286|cit286","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P on behalf of the Cochrane Applicability and Recommendations Methods Group Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD007929.pub4-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"259","DOI":"10.11124\/JBISRIR-D-19-00059","article-title":"Interactive summary of findings tables: the way to present and understand results of systematic reviews","volume":"17","author":"Schunemann H","year":"2019","journal-title":"JBI Database Systematic Reviews and Implementation Reports"},{"issue":"3","key":"10.1002\/14651858.CD007929.pub4-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"BSR20192226","DOI":"10.1042\/BSR20192226","article-title":"Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials","volume":"40","author":"Shao","year":"2020","journal-title":"Bioscience Reports"},{"issue":"6","key":"10.1002\/14651858.CD007929.pub4-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"8975","DOI":"10.18632\/aging.202724","article-title":"PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival","volume":"13","author":"Shao","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"175883591878850","DOI":"10.1177\/1758835918788500","article-title":"Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis","volume":"10","author":"Sjoquist","year":"2018","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0291|cit291","first-page":"83","article-title":"The Era of PARP inhibitors in ovarian cancer: \"Class Action\" or not? A systematic review and meta-analysis","volume":"131","author":"Staropoli","year":"2018","journal-title":"CriticalReviews in Oncology\/ Hematology"},{"issue":"1","key":"10.1002\/14651858.CD007929.pub4-BIB0292|cit292","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001418","article-title":"Chemotherapy for advanced ovarian cancer","author":"Stewart","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD007929.pub4-BIB0293|cit293","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/jcph.1875","article-title":"A population pharmacokinetic meta-analysis of veliparib, a PARP inhibitor, across phase 1\/2\/3 trials in cancer patients","volume":"61","author":"Stodtmann","year":"2021","journal-title":"Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD007929.pub4-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/jcpt.13300","article-title":"Gastrointestinal events with PARP inhibitors in cancer patients: a meta-analysis of phase II\/III randomized controlled trials","volume":"46","author":"Sun","year":"2021","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD007929.pub4-BIB0295|cit295","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1038\/s41598-020-59671-3","article-title":"Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma","volume":"1","author":"Takaya","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0296|cit296","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"58","author":"Cancer Genome Atlas Research Network","year":"2016","journal-title":"Nature\u00a0"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"101909","DOI":"10.1016\/j.ctrv.2019.101909","article-title":"Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status","volume":"80","author":"Tomao","year":"2019","journal-title":"Cancer Treatment Reviews"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3389\/fonc.2020.01204","article-title":"PARP inhibitors in patients with newly diagnosed advanced ovarian cancer: a meta-analysis of randomized clinical trials","volume":"10","author":"Wang","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"573801","DOI":"10.3389\/fonc.2020.573801","article-title":"Comparative efficacy and safety of parp inhibitors as maintenance therapy in platinum sensitive recurrent ovarian cancer: a network meta-analysis","volume":"10","author":"Xu","year":"2020","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007929.pub4-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12957-020-01931-7","article-title":"The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis","volume":"18","author":"Yang","year":"2020","journal-title":"World Journal of Surgical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD007929.pub4-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/ijc.32143","article-title":"Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas","volume":"145","author":"Yi","year":"2019","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD007929.pub4-BIB0302|cit302","doi-asserted-by":"publisher","first-page":"vi89","DOI":"10.1093\/annonc\/mdz339.028","article-title":"Avelumab in platinum-resistant\/refractory ovarian cancer (PRROC): phase 3 results from JAVELIN Ovarian 200","volume":"30","author":"Yonemori","year":"2019","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD007929.pub4-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2174\/187152007781668715","article-title":"PARP inhibitor development for systemic cancer targeting","volume":"7","author":"Zaremba","year":"2007","journal-title":"Anti-cancer Agents in Medicinal Chemistry"},{"issue":"3","key":"10.1002\/14651858.CD007929.pub4-BIB0304|cit304","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007929","article-title":"DNA-repair pathway inhibitors for the treatment of ovarian cancer","author":"Martinek","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD007929.pub4-BIB0305|cit305","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007929.pub2","article-title":"DNA-repair pathway inhibitors for the treatment of ovarian cancer","author":"Martinek","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD007929.pub4-BIB0306|cit306","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007929.pub3","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.","author":"Wiggans","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T15:21:03Z","timestamp":1726672863000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007929.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":306,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007929.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]}}}